#Bristol Myers Squibb

ViiV Healthcare recently acquired Bristol-Myers Squibb’s (BMS) portfolio of HIV antiretrovirals (ARVs) in the pipeline.

The sale includes an HIV attachment inhibitor called fostemsavir and a maturation inhibitor, both in late-stage development.

A placebo-controlled Phase IIa study of BMS-955176 has shown that the experimental ARV is potent, safe and well-tolerated.

Here’s what’s in store this year for new hepatitis C therapies, as well as approvals for new uses of existing treatments.

ViiV Healthcare has announced plans to acquire the portfolio of HIV antiretrovirals Bristol-Myers Squibb has in development.

Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

Daklinza (daclatasvir) and Sovaldi (sofosbuvir) more effectively cures hepatitis C among those coinfected with HIV than does Sovaldi and...

The FDA as given priority review status to Bristol-Myers Squibb’s applications for new indication approvals for the hep C drug virus...